Anbio Biotechnology
NNNN Nasdaq· In Vitro & In Vivo Diagnostic Substances
KIRA · Stoqly’s AI analyst, in plain words
- Anbio Biotechnology had $8.6M of revenue in fiscal 2025, up 5.6% on the year before.
- Its operating margin was 66.7%, up 42.3 pts: of every 100 in sales, about 67 is left after running the business.
- Anbio Biotechnology made $6.4M of net profit in fiscal 2025. From fiscal 2022 to 2025, diluted EPS grew −98.9% a year.
Market cap
—
P/E
—
Revenue
$8.6M
Net income
$6.4M
Free cash flow
—
Operating margin
66.7%
Anbio Biotechnology in 30 seconds · fiscal 2025
Are sales growing?
+5.6%
Yes. Sales grew 5.6% last year.
Does it make a profit?
74.1%
Yes. It keeps 74.1% of every sale as profit.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
What Anbio Biotechnology does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 7, 2026
- Legal name
- Anbio Biotechnology
- CIK
- 0001982708
Anbio Biotechnology · NNNN
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $23.5M | $6.7M | $8.2M | $8.6M |
| Revenue growth | — | −71.5% | 21.9% | 5.6% |
| Gross margin | 53.4% | 50.1% | 71.9% | 87.2% |
| Operating margin | 43.3% | 29.2% | 24.4% | 66.7% |
| Net income | $10.0M | $2.3M | $2.4M | $6.4M |
| Net margin | 42.5% | 33.6% | 29.0% | 74.1% |
| Diluted EPS | $100,112.00 | $0.11 | $0.06 | $0.15 |
| Cash | ||||
| Cash from operations | $4.4M | $0.9M | $2.1M | −$6.7M |
| Share count change | — | — | 97.3% | 3.3% |
| Debt and strength | ||||
| Cash and short-term investments | $7.1M | $9.7M | $11.8M | $11.9M |
| Shareholders' equity | $12.5M | $14.8M | $17.2M | $30.2M |
| Current ratio | — | 15.9x | 10.7x | 344.5x |
| Interest coverage | 1,274.5x | — | — | — |
| Returns and quality | ||||
| Return on equity | 79.8% | 16.5% | 14.8% | 27.0% |
| Return on tangible equity | 79.8% | 15.2% | 13.8% | 21.2% |
| Piotroski F-score | — | — | 4 | 4 |
| Altman Z'' | — | 25.7 | 19.9 | 371.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Anbio Biotechnology · NNNN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001982708). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.